Ready To Get Started?
We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.
Or call (215) 966-6061
Questions? Call: 215-966-6061
MAbs against GPCRs, Ion Channels &Transporters
>95% success rate
20+ years expertise focused on difficult targets
Home » MPS Antibody Discovery
The MPS antibody discovery platform is specifically designed to generate the most diverse antibodies against even the most difficult targets, with a success rate of >95%.
These antibodies are delivered to you as validated and well-characterized lead molecules in bispecific and other formats, ready for IND-enabling studies.
Bring us your difficult targets, membrane proteins, highly conserved proteins, and functional epitopes.
MPS is the only antibody discovery platform specifically built for challenging protein targets, such as GPCRs, ion channels, and transporters—targets that many consider undruggable. It’s the platform we’ve used to develop the assets in our own therapeutic pipeline.
But the MPS platform delivers MAbs against all types of protein targets. That’s because it’s built on high-quality antigen, an evolutionarily divergent immunization host that yields large, diverse panels of candidates, and deep biology expertise in creating lead candidates.
“Access to Integral Molecular’s capabilities complements our ability to advance our therapeutic pipeline, which is dedicated to delivering novel antibody therapeutics to patients.”
-CECILE GEUIJEN, PhD, SVP & CHIEF SCIENTIFIC OFFICER OF ONCOLOGY RESEARCH, MERUS
All of our antibodies are humanized using our one-step hCAT platform, with high affinity, high specificity, and documented developability, giving you therapeutic lead candidates 12-18 months from IND.
To learn more about how MPS delivers these features and more, visit the pages in the Technology section.
“We have been impressed by Integral Molecular’s membrane protein expertise and their proven record in discovering antibodies against membrane proteins.”
-HIDEAKI TADA, EXECUTIVE DIRECTOR, CENTER OF ONCOLOGY RESEARCH, ONO PHARMACEUTICAL CO., LTD.
For more case studies, publications, and webinars, visit the Resources page
The MPS Antibody Discovery platform overcomes three key barriers to enable success: presenting native epitopes, making the target highly immunogenic, and generating MAbs against diverse epitopes. Optimizing the antigen and immunization strategy are critically important for downstream success. The MPS Antibody Discovery platform overcomes challenges associated with membrane proteins such as poor expression, trafficking, toxicity, and preservation of native conformation. As the inventors of Lipoparticles, we begin your project with the highest-quality antigen available for immunization and discovery. Our innovative immunization protocols includes the use of divergent species (chickens), DNA, mRNA, and Lipoparticles (VLPs) to preserve the structure of the antigen, proprietary adjuvants, and phage protocols optimized for membrane protein challenges. This system is proven to elicit a robust, diverse, and focused immune responses on relevant extracellular epitopes. We routinely isolate high-affinity, humanized MAbs against highly conserved membrane protein targets, with unique characteristics including state-specific binding and functional activity.
Yes, the MPS platform delivers fully humanized MAbs. Healthy, outbred, wild-type chickens are excellent immunization hosts, producing robust immune responses and offering excellent opportunities for MAb diversity while overcoming homology challenges associated with mammalian hosts. Chicken antibody frameworks are highly amenable to humanization. With our Humanized Chicken Antibody Discovery technology (hCAT), antibody CDR’s from responsive chickens are humanized prior to the creation of immune libraries used for phage panning. Thus, hits isolated from screening are already fully humanized, eliminating the time and cost required for downstream engineering. The result is high-affinity, fully humanized MAbs ready for preclinical characterization.
Integral Molecular is also a Certified Service Provider of Alloy Therapeutics, offering immunization in ATX-GxTM transgenic, immunocompetent mice which produce human antibodies.
The final deliverable of an MPS Antibody Discovery project is usually a selection of well-characterized, high affinity, highly specific, humanized therapeutic lead candidates that meet the customer’s specifications.
In addition to the final deliverable, customers may elect to receive progress reports during their MPS project, such as for:
Yes, we offer custom Lipoparticle services, as well as a catalog of pre-validated ReadyReceptor Lipoparticles. More information is available on our Lipoparticles page. Contact us to discuss your protein of interest and how Lipoparticles can unleash your research and discovery projects.
We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.
Join Our Mailing List